医学
恶性肿瘤
免疫疗法
靶向治疗
人口
肿瘤科
癌症
内科学
生物信息学
重症监护医学
生物
环境卫生
作者
Matthew J. Hadfield,Kathryn DeCarli,K. Bash,Grace Sun,Khaldoun Almhanna
摘要
Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody–drug conjugates. This review provides an overview of the current landscape of treatment options, as well as promising future therapeutic targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI